{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T20:11:58Z","timestamp":1790194318617,"version":"4.1.0"},"reference-count":97,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2023,2,15]],"date-time":"2023-02-15T00:00:00Z","timestamp":1676419200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pathogens"],"abstract":"<jats:p>Chronic recipients of plasma products are at risk of infection from blood-borne pathogens as a result of their inevitable exposure to agents which will contaminate a plasma manufacturing pool made up of thousands of individual donations. The generation of such a pool is an essential part of the large-scale manufacture of these products and is required for good manufacturing practice (GMP). Early observations of the transmission of hepatitis by pooled plasma and serum led to the incorporation of heat treatment of the albumin solution produced by industrial Cohn fractionation of plasma. This led to an absence of pathogen transmission by albumin over decades, during which hepatitis continued to be transmitted by other early plasma fractions, as well as through mainstream blood transfusions. This risk was decreased greatly over the 1960s as an understanding of the epidemiology and viral aetiology of transfusion-transmitted hepatitis led to the exclusion of high-risk groups from the donor population and the development of a blood screening test for hepatitis B. Despite these measures, the first plasma concentrates to treat haemophilia transmitted hepatitis B and other, poorly understood, forms of parenterally transmitted hepatitis. These risks were considered to be acceptable given the life-saving nature of the haemophilia treatment products. The emergence of the human immunodeficiency virus (HIV) as a transfusion-transmitted infection in the early 1980s shifted the focus of attention to this virus, which proved to be vulnerable to a number of inactivation methods introduced during manufacture. Further developments in the field obviated the risk of hepatitis C virus (HCV) which had also infected chronic recipients of plasma products, including haemophilia patients and immunodeficient patients receiving immunoglobulin. The convergence of appropriate donor selection driven by knowledge of viral epidemiology, the development of blood screening now based on molecular diagnostics, and the incorporation of viral inactivation techniques in the manufacturing process are now recognised as constituting a \u201csafety tripod\u201d of measures contributing to safety from pathogen transmission. Of these three components, viral inactivation during manufacture is the major contributor and has proven to be the bulwark securing the safety of plasma derivatives over the past thirty years. Concurrently, the safety of banked blood and components continues to depend on donor selection and screening, in the absence of universally adopted pathogen reduction technology. This has resulted in an inversion in the relative safety of the products of blood banking compared to plasma products. Overall, the experience gained in the past decades has resulted in an absence of pathogen transmission from the current generation of plasma derivatives, but maintaining vigilance, and the surveillance of the emergence of infectious agents, is vital to ensure the continued efficacy of the measures in place and the development of further interventions aimed at obviating safety threats.<\/jats:p>","DOI":"10.3390\/pathogens12020318","type":"journal-article","created":{"date-parts":[[2023,2,15]],"date-time":"2023-02-15T02:01:10Z","timestamp":1676426470000},"page":"318","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["The Evolution of the Safety of Plasma Products from Pathogen Transmission\u2014A Continuing Narrative"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0804-7463","authenticated-orcid":false,"given":"Albert","family":"Farrugia","sequence":"first","affiliation":[{"name":"UWA Medical School, Surgery The University of Western Australia, 35 Stirling Highway, Perth 6009, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,2,15]]},"reference":[{"key":"ref_1","unstructured":"Kendrick, D.B. (1964). Blood Program in World War II, Office of the Surgeon General: Department of the Army."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.iac.2008.06.004","article-title":"History of Immunoglobulin Replacement","volume":"28","author":"Eibl","year":"2008","journal-title":"Immunol. Allergy Clin. N. Am."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1111\/hae.13645","article-title":"Samuel Armstrong Lane\u2019s first successful treatment of haemophilia with blood transfusion in 1840: Could this also be the first successful bypassing therapy?","volume":"25","author":"Poon","year":"2018","journal-title":"Haemophilia"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1365-3148.1991.tb00002.x","article-title":"Oliver Memorial Lecture 1989. The evolution and future of haemophilia therapy","volume":"1","author":"Bloom","year":"1991","journal-title":"Transfus. Med. Oxf. Engl."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1093\/jhmas\/jrh078","article-title":"Joseph S. Edwin J. Cohn and the Development of Protein Chemistry: With a Detailed Account of His Work on the Fractionation of Blood during and after World War II review","volume":"59","author":"Fruton","year":"2004","journal-title":"J. Hist. Med. Allied Sci."},{"key":"ref_6","unstructured":"Cohn, E.J. (1948). Advances in Military Medicine, Little, Brown and Co."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1021\/ja01207a034","article-title":"Preparation and Properties of Serum and Plasma Proteins. IV. A System for the Separation into Fractions of the Protein and Lipoprotein Components of Biological Tissues and Fluids","volume":"68","author":"Cohn","year":"1946","journal-title":"J. Am. Chem. Soc."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1016\/j.xphs.2022.03.005","article-title":"Therapeutic Solutions of Human Albumin\u2014The Possible Effect of Process-Induced Molecular Alterations on Clinical Efficacy and Safety","volume":"111","author":"Farrugia","year":"2022","journal-title":"J. Pharm. Sci."},{"key":"ref_9","unstructured":"Kendrick, D. (2021, October 07). The Bovine and Human Albumin Programs. In Blood Program in World War II\u2014Digital Collections\u2014National Library of Medicine [Internet], Available online: https:\/\/collections.nlm.nih.gov\/catalog\/nlm:nlmuid-0014773-bk."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1136\/bmj.2.4889.676","article-title":"Acquired afibrinogenaemia complicating pregnancy; report of two cases of two cases of concealed accidental haemorrhage treated by human fibrinogen","volume":"2","author":"Barnett","year":"1954","journal-title":"Br. Med. J."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1542\/peds.9.6.722","article-title":"Agammaglobulinemia","volume":"9","author":"Bruton","year":"1952","journal-title":"Pediatrics"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"33","DOI":"10.21037\/aob.2018.05.03","article-title":"An overview of plasma fractionation","volume":"3","author":"Burnouf","year":"2018","journal-title":"Ann. Blood"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"213","DOI":"10.15171\/ijb.1401","article-title":"Implementation of Plasma Fractionation in Biological Medicines Production","volume":"14","author":"Ghasemzadeh","year":"2016","journal-title":"Iran J. Biotechnol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1046\/j.1537-2995.1996.36996420751.x","article-title":"Considerations of pool size in the manufacture of plasma derivatives","volume":"36","author":"Lynch","year":"2003","journal-title":"Transfusion"},{"key":"ref_15","first-page":"337","article-title":"Transfusion malaria","volume":"50","year":"1974","journal-title":"Bull. World Health Organ."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1136\/bmj.1.4075.264","article-title":"Transmission of Syphilis by Blood Transfusion","volume":"1","author":"McCluskie","year":"1939","journal-title":"BMJ"},{"key":"ref_17","first-page":"20","article-title":"Eine icterusepidemic","volume":"22","author":"Lurman","year":"1885","journal-title":"Berl Klin Wochenschr."},{"key":"ref_18","unstructured":"Regan, F.A.M., Barbara, J.A.J., and Contreras, M. (2008). Transfusion Microbiology [Internet], Cambridge University Press. Available online: https:\/\/www.cambridge.org\/core\/books\/transfusion-microbiology\/fractionated-products\/A3F5C27C822FADCA41D4FA78184744D4."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1001\/jama.1943.02840170016005","article-title":"Jaundice occurring one to four months after transfusion of blood or plasma: Report of seven cases","volume":"121","author":"Beeson","year":"1943","journal-title":"J. Am. Med. Assoc."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1001\/jama.1947.02880270001001","article-title":"homologous serum jaundice: A Problem in the Operation of Blood Banks","volume":"134","author":"Scheinberg","year":"1947","journal-title":"J. Am. Med. Assoc."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1172\/JCI101939","article-title":"Chemical, clinical, and immunological studies on the products of human plasma fractionation. Xxxvi. Inactivation of the virus of homologous serum hepatitis in solutions of normal human serum albumin by means of heat","volume":"27","author":"Gellis","year":"1948","journal-title":"J. Clin. Investig."},{"key":"ref_22","first-page":"1145","article-title":"The problem of reducing the danger of serum; hepatitis from blood and blood products","volume":"55","author":"Murray","year":"1955","journal-title":"N. Y. State J. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1046\/j.1537-2995.1976.16276155108.x","article-title":"Hepatitis B virus and hepatitis B surface antigen in human albumin products","volume":"16","author":"Hoofnagle","year":"1976","journal-title":"Transfusion"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1093\/clinchem\/43.8.1487","article-title":"History of posttransfusion hepatitis","volume":"43","author":"Tobler","year":"1997","journal-title":"Clin. Chem."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1093\/infdis\/123.3.279","article-title":"Development and Persistence of Antibody to Hepatitis-Associated (Australia) Antigen in Patients with Hemophilia","volume":"123","author":"Seeler","year":"1971","journal-title":"J. Infect. Dis."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"386","DOI":"10.2307\/2529402","article-title":"347. Note: Estimation of the Probability of Post Transfusion Hepatitis in Hemophilia Treatment","volume":"29","author":"Davis","year":"1973","journal-title":"Biometrics"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0887-7963(05)80030-6","article-title":"Paid-versus-volunteer blood donation in the united states: A historical review","volume":"9","author":"Domen","year":"1995","journal-title":"Transfus. Med. Rev."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1126\/science.2523562","article-title":"Isolation of a cDNA cLone Derived from a Blood-Borne Non-A, Non-B Viral Hepatitis Genome","volume":"244","author":"Choo","year":"1989","journal-title":"Science"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1136\/bmj.287.6407.1754","article-title":"Non-A non-B hepatitis after transfusion of factor VIII in infrequently treated patients","volume":"287","author":"Fletcher","year":"1983","journal-title":"BMJ"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/S0140-6736(82)91105-9","article-title":"Hepatitis and Haemophilia Therapy in Australia","volume":"320","author":"Rickard","year":"1982","journal-title":"Lancet"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/bjh.17438","article-title":"Viral hepatitis in haemophilia: Historical perspective and current management","volume":"195","author":"Isfordink","year":"2021","journal-title":"Br. J. Haematol."},{"key":"ref_32","unstructured":"Leveton, L.B., Harold CSox, J., and Stoto, M.A. (2023, January 13). History of the Controversy [Internet]. HIV And The Blood Supply: An Analysis of Crisis Decisionmaking, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK232419\/."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1111\/j.1538-7836.2006.02213.x","article-title":"The tragic history of AIDS in the hemophilia population, 1982\u20131984","volume":"4","author":"Evatt","year":"2006","journal-title":"J. Thromb. Haemost. JTH"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1046\/j.1537-2995.1991.31191096183.x","article-title":"Risk of human immunodeficiency virus (HIV) transmission by blood transfusions before the implementation of HIV-1 antibody screening. The Transfusion Safety Study Group","volume":"31","author":"Busch","year":"1991","journal-title":"Transfusion"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"401","DOI":"10.7326\/0003-4819-98-3-401","article-title":"Acquired Immune Deficiency Syndrome: The Past as Prologue","volume":"98","author":"Curran","year":"1983","journal-title":"Ann. Intern. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1046\/j.1537-2995.2001.41030338.x","article-title":"Risk factors for infection with HBV and HCV in a largecohort of hemophiliac males","volume":"41","author":"Soucie","year":"2001","journal-title":"Transfusion"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/j.1600-0609.1987.tb00162.x","article-title":"HIV infection in Norwegian haemophiliacs: The prevalence of antibodies against HIV in haemophiliacs treated with lyophilized cryoprecipitate from volunteer donors","volume":"39","author":"Evensen","year":"2009","journal-title":"Eur. J. Haematol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1007\/BF01967219","article-title":"Prevalence of antibodies against hepatitis C virus in Norwegians with congenital coagulation factor defects treated with plasma products from small pools","volume":"9","author":"Rollag","year":"1990","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"675","DOI":"10.3109\/00365549109024292","article-title":"Prevalence of antibodies against parvovirus B19 in Norwegians with congenital coagulation factor defects treated with plasma products from small donor pools","volume":"23","author":"Rollag","year":"1991","journal-title":"Scand J. Infect. Dis."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Haemophilia Study Group (1988). Haemophilia, HIV Infection, and Blood Transfusion in Belgium. Acta Clin. Belg., 43, 95\u2013100.","DOI":"10.1080\/17843286.1988.11717915"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/jmv.1890450302","article-title":"Hepatitis C infection and viremia in Dutch Hemophilia patients","volume":"45","author":"Roosendaal","year":"1995","journal-title":"J. Med. Virol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e361","DOI":"10.1016\/S2352-3018(16)30087-X","article-title":"Estimates of global, regional, and national incidence, prevalence, and mortality of HIV, 1980\u20132015: The Global Burden of Disease Study 2015","volume":"3","author":"Wang","year":"2016","journal-title":"Lancet HIV"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1128\/CVI.00053-16","article-title":"Human Immunodeficiency Virus Diagnostic Testing: 30 Years of Evolution","volume":"23","author":"Alexander","year":"2016","journal-title":"Clin. Vaccine Immunol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/hae.12100","article-title":"History of prophylaxis","volume":"19","author":"Berntorp","year":"2013","journal-title":"Haemophilia"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1046\/j.1537-2995.2002.00183.x","article-title":"NAT screening of blood and plasma donations: Evolution of technology and regulatory policy*","volume":"42","author":"Tabor","year":"2002","journal-title":"Transfusion"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1111\/j.1365-2516.2004.00911.x","article-title":"Plasma for fractionation: Safety and quality issues","volume":"10","author":"Farrugia","year":"2004","journal-title":"Haemophilia"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Sibinga, C.T.h.S., and Cash, J.D. (2001). Transfusion Medicine: Quo Vadis? What Has Been Achieved, What Is to Be Expected: Proceedings of the jubilee Twenty-Fifth International Symposium on Blood Transfusion, Groningen, 2000, Springer. (Developments in Hematology and Immunology).","DOI":"10.1007\/978-1-4615-1735-1"},{"key":"ref_48","first-page":"619","article-title":"Factor VIII concentrate, highly purified and heated in solution (author\u2019s transl)","volume":"31","author":"Heimburger","year":"1981","journal-title":"Arzneimittelforschung"},{"key":"ref_49","first-page":"303","article-title":"Virus safety of pasteurized factor VIII and factor IX concentrates: Study in virgin patients","volume":"67","author":"Heimburger","year":"1987","journal-title":"Dev. Biol. Stand."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0140-6736(85)91043-8","article-title":"Absence of antibodies to aids virus in haemophiliacs treated with heat-treated factor viii concentrate","volume":"325","author":"Rouzioux","year":"1985","journal-title":"Lancet"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0140-6736(85)90055-8","article-title":"Transmission Of Non-A, Non-B Hepatitis By Heat-Treated Factor Viii Concentrate","volume":"326","author":"Colombo","year":"1985","journal-title":"Lancet"},{"key":"ref_52","first-page":"323","article-title":"Interim results of surveillance for NANBH in patients receiving heated concentrates produced in England","volume":"67","author":"Smith","year":"1987","journal-title":"Dev. Biol. Stand."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/j.1423-0410.1989.tb01144.x","article-title":"Severely Heated Therapeutic Factor VIII Concentrate of High Specific Activity","volume":"57","author":"Winkelmana","year":"1989","journal-title":"Vox Sang."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1046\/j.1537-2995.1985.25686071422.x","article-title":"Inactivation of viruses in labile blood derivatives. I. Disruption of lipid-enveloped viruses by tri(n-butyl)phosphate detergent combinations","volume":"25","author":"Horowitz","year":"1985","journal-title":"Transfusion"},{"key":"ref_55","first-page":"147","article-title":"Viral safety of solvent-detergent treated blood products","volume":"81","author":"Horowitz","year":"1993","journal-title":"Dev. Biol. Stand."},{"key":"ref_56","first-page":"202","article-title":"Use of Concentrated Human Serum gamma-Globulin in the Prevention and Attenuation of Measles","volume":"21","author":"Janeway","year":"1945","journal-title":"Bull. N. Y. Acad. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"554","DOI":"10.3181\/00379727-83-20415","article-title":"Safety of Immune Serum Globulin with Respect to Homologous Serum Hepatitis","volume":"83","author":"Murray","year":"1953","journal-title":"Exp. Biol. Med."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1136\/bmj.2.4722.6","article-title":"Homologous serum hepatitis and measles prophylaxis; a report to the Medical Research Council","volume":"2","author":"Cockburn","year":"1951","journal-title":"Br. Med. J."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1093\/infdis\/135.2.252","article-title":"Hepatitis B in Subjects Treated with a Drug Containing Immunoglobulins","volume":"135","author":"Petrilli","year":"1977","journal-title":"J. Infect. Dis."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/S0140-6736(79)92296-7","article-title":"Transmission of Hepatitis B by Immune Serum Globulin","volume":"314","author":"Tabor","year":"1979","journal-title":"Lancet"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/0168-8278(91)90076-N","article-title":"Long-term persistence of hepatitis C virus antibodies in a single source outbreak","volume":"13","author":"Dittmann","year":"1991","journal-title":"J. Hepatol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1056\/NEJM199904223401602","article-title":"Clinical Outcomes after Hepatitis C Infection from Contaminated Anti-D Immune Globulin","volume":"340","year":"1999","journal-title":"New Engl. J. Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/cei.1996.104.s1.35","article-title":"The viral safety of intravenous immune globulin","volume":"104","author":"Yap","year":"1996","journal-title":"Clin. Exp. Immunol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"665","DOI":"10.3389\/fimmu.2014.00665","article-title":"Manufacture of Immunoglobulin Products for Patients with Primary Antibody Deficiencies \u00e2\u20ac\u201c The Effect of Processing Conditions on Product Safety and Efficacy","volume":"5","author":"Farrugia","year":"2014","journal-title":"Front. Immunol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1046\/j.1537-2995.1992.32993110753.x","article-title":"Partitioning of hepatitis C virus during Cohn-Oncley fractionation of plasma","volume":"32","author":"Yei","year":"1992","journal-title":"Transfusion"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1046\/j.1537-2995.1994.34794330014.x","article-title":"Detection and characterization of hepatitis C virus RNA in immune globulins","volume":"34","author":"Yu","year":"1994","journal-title":"Transfusion"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0149-2918(96)80197-4","article-title":"Safety of intravenous immunoglobulin with regard to hepatitis c virus","volume":"18","author":"Yu","year":"1996","journal-title":"Clin. Ther."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"7705","DOI":"10.1073\/pnas.0402458101","article-title":"Neutralizing antibodies to hepatitis C virus (HCV) in immune globulins derived from anti-HCV-positive plasma","volume":"101","author":"Yu","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/S0140-6736(83)90496-8","article-title":"NON-A, non-B Hepatitis from Intravenous Immunoglobulin","volume":"322","author":"Lane","year":"1983","journal-title":"Lancet"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1093\/oxfordjournals.bmb.a072644","article-title":"Overview of the transmissible spongiform encephalopathies: Prion protein disorders","volume":"49","author":"DeArmond","year":"1993","journal-title":"Br. Med Bull."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1046\/j.1537-2995.1998.38998408999.x","article-title":"The distribution of infectivity in blood components and plasma derivatives in experimental models of transmissible spongiform encephalopathy","volume":"38","author":"Brown","year":"1998","journal-title":"Transfusion"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.biologicals.2003.08.004","article-title":"Partitioning of TSE infectivity during ethanol fractionation of human plasma","volume":"32","author":"Gregori","year":"2004","journal-title":"Biologicals"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1111\/trf.15751","article-title":"No evidence of transfusion transmitted sporadic Creutzfeldt-Jakob disease: Results from a bi-national cohort study","volume":"60","author":"Holmqvist","year":"2020","journal-title":"Transfusion"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/S0140-6736(00)02719-7","article-title":"Transmission of BSE by blood transfusion in sheep","volume":"356","author":"Houston","year":"2000","journal-title":"Lancet"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/vox.12371","article-title":"Creutzfeldt-Jakob disease and blood transfusion: Updated results of the UK Transfusion Medicine Epidemiology Review Study","volume":"110","author":"Urwin","year":"2015","journal-title":"Vox Sang."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1046\/j.1537-2995.2001.41040449.x","article-title":"A direct relationship between the partitioning of the pathogenic prion protein and transmissible spongiform encephalopathy infectivity during the purification of plasma proteins","volume":"41","author":"Lee","year":"2001","journal-title":"Transfusion"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/j.1365-2516.2009.02181.x","article-title":"Variant CJD infection in the spleen of a neurologically asymptomatic UK adult patient with haemophilia","volume":"16","author":"Peden","year":"2010","journal-title":"Haemophilia"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1111\/j.1423-0410.2008.01148.x","article-title":"A recipient of immunoglobulin from a donor who developed vCJD","volume":"96","author":"Jolles","year":"2009","journal-title":"Vox Sang."},{"key":"ref_79","unstructured":"UK Department of Health and Social Care (2023, January 17). Ban Lifted to Allow UK Blood Plasma to Be Used for Life-Saving Treatments [Internet]. GOV.UK, Available online: https:\/\/www.gov.uk\/government\/news\/ban-lifted-to-allow-uk-blood-plasma-to-be-used-for-life-saving-treatments."},{"key":"ref_80","unstructured":"US Department of Health and Human Services (2023, January 17). Recommendations To Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease and Variant Creutzfeldt-Jakob Disease by Blood and Blood Components [Internet], Available online: https:\/\/www.govinfo.gov\/content\/pkg\/FR-2022-05-24\/html\/2022-11119.htm."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1111\/vox.12631","article-title":"Creutzfeldt-Jakob disease and blood transfusion safety","volume":"113","author":"Seed","year":"2018","journal-title":"Vox Sang."},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Levi, J.E. (2018). Emerging Infectious Agents and Blood Safety in Latin America. Front. Med., 5, Available online: https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2018.00071\/full.","DOI":"10.3389\/fmed.2018.00071"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.blre.2008.10.004","article-title":"Globalisation and blood safety","volume":"23","author":"Farrugia","year":"2009","journal-title":"Blood Rev."},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Abebe, G.M. (2020). Emerging and Re-Emerging Viral Diseases: The Case of Coronavirus Disease-19 (COVID-19). Int. J. Virol. AIDS, 7, Available online: https:\/\/www.clinmedjournals.org\/articles\/ijva\/international-journal-of-virology-and-aids-ijva-7-067.php?jid=ijva.","DOI":"10.23937\/2469-567X\/1510067"},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Gim\u00e9nez-Richarte, \u00c1., de Salazar, M.I.O., Gim\u00e9nez-Richarte, M.-P., Collado, M., Fern\u00e1ndez, P.L., Clavijo, C., Navarro, L., Arbona, C., Marco, P., and Ramos-Rincon, J.-M. (2022). Transfusion-transmitted arboviruses: Update and systematic review. PLOS Neglected Trop. Dis., 16.","DOI":"10.1371\/journal.pntd.0010843"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1046\/j.1537-2995.2003.00496.x","article-title":"West Nile virus and the safety of plasma derivatives: Verification of high safety margins, and the validity of predictions based on model virus data","volume":"43","author":"Kreil","year":"2003","journal-title":"Transfusion"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1111\/j.1537-2995.2012.03565.x","article-title":"Chikungunya virus and the safety of plasma products","volume":"52","author":"Leydold","year":"2012","journal-title":"Transfusion"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/trf.13343","article-title":"Hepatitis E virus and the safety of plasma products: Investigations into the reduction capacity of manufacturing processes","volume":"56","author":"Farcet","year":"2015","journal-title":"Transfusion"},{"key":"ref_89","unstructured":"Centers for Disease Control and Prevention (CDC) (2010). Transfusion-related transmission of yellow fever vaccine virus--California, 2009. MMWR Morb. Mortal. Wkly. Rep., 59, 34\u201337."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1111\/trf.17224","article-title":"Second hepatitis C virus transmission by blood components since introduction of mandatory NAT screening in Germany","volume":"63","author":"Himmelsbach","year":"2022","journal-title":"Transfusion"},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Schmidt, M., Korn, K., N\u00fcbling, M., Chudy, M., Kress, J., Horst, H., Geusendam, G., Hennig, H., Sireis, W., and Rabenau, H. (2009). First transmission of human immunodeficiency virus Type 1 by a cellular blood product after mandatory nucleic acid screening in Germany. Transfusion, 49, Available online: https:\/\/pubmed.ncbi.nlm.nih.gov\/19453990\/.","DOI":"10.1111\/j.1537-2995.2009.02203.x"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.0042-9007.2004.00386.x","article-title":"The mantra of blood safety: Time for a new tune?","volume":"86","author":"Farrugia","year":"2004","journal-title":"Vox Sang."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1111\/vox.13267","article-title":"Plasma procurement and plasma product safety in light of the COVID-19 pandemic from the perspective of the plasma industry","volume":"117","author":"Turecek","year":"2022","journal-title":"Vox Sang."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.hoc.2019.05.001","article-title":"Pathogen Reduction: The State of the Science in 2019","volume":"33","author":"Gehrie","year":"2019","journal-title":"Hematol. Oncol. Clin. N. Am."},{"key":"ref_95","unstructured":"Institute of Medicine (US) Committee to Study HIV Transmission Through Blood and Blood Products, Leveton, L.B., Harold CSox, J., and Stoto, M.A. (2023, January 18). Executive Summary [Internet]. HIV And The Blood Supply: An Analysis Of Crisis Decisionmaking, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK232406\/."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000057291","article-title":"Disease Transmission by Blood Products: Past, Present and Future","volume":"32","author":"Murphy","year":"2002","journal-title":"Pathophysiol. Haemost. Thromb."},{"key":"ref_97","unstructured":"United Kingdom Government (2023, January 19). Homepage | Infected Blood Inquiry [Internet]. Available online: https:\/\/www.infectedbloodinquiry.org.uk\/."}],"container-title":["Pathogens"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-0817\/12\/2\/318\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:35:47Z","timestamp":1760121347000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-0817\/12\/2\/318"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,15]]},"references-count":97,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,2]]}},"alternative-id":["pathogens12020318"],"URL":"https:\/\/doi.org\/10.3390\/pathogens12020318","relation":{},"ISSN":["2076-0817"],"issn-type":[{"value":"2076-0817","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,15]]}}}